- Home
- AMRN vs MOLN Comparison
AMRN vs MOLN Comparison
Compare AMRN & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- MOLN
- Stock Information
- Founded
- AMRN 1989
- MOLN 2004
- Country
- AMRN Ireland
- MOLN Switzerland
- Employees
- AMRN N/A
- MOLN N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- AMRN Health Care
- MOLN
- Exchange
- AMRN Nasdaq
- MOLN Nasdaq
- Market Cap
- AMRN 189.2M
- MOLN 195.4M
- IPO Year
- AMRN 1993
- MOLN 2021
- Fundamental
- Price
- AMRN $0.64
- MOLN $5.33
- Analyst Decision
- AMRN Buy
- MOLN
- Analyst Count
- AMRN 1
- MOLN 0
- Target Price
- AMRN N/A
- MOLN N/A
- AVG Volume (30 Days)
- AMRN 1.6M
- MOLN 6.4K
- Earning Date
- AMRN 02-27-2025
- MOLN 03-13-2025
- Dividend Yield
- AMRN N/A
- MOLN N/A
- EPS Growth
- AMRN N/A
- MOLN N/A
- EPS
- AMRN N/A
- MOLN N/A
- Revenue
- AMRN $241,021,000.00
- MOLN $7,105,397.00
- Revenue This Year
- AMRN N/A
- MOLN N/A
- Revenue Next Year
- AMRN N/A
- MOLN $29.41
- P/E Ratio
- AMRN N/A
- MOLN N/A
- Revenue Growth
- AMRN N/A
- MOLN N/A
- 52 Week Low
- AMRN $0.43
- MOLN $3.32
- 52 Week High
- AMRN $1.37
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- AMRN 69.66
- MOLN 49.09
- Support Level
- AMRN $0.43
- MOLN $5.25
- Resistance Level
- AMRN $0.49
- MOLN $5.91
- Average True Range (ATR)
- AMRN 0.04
- MOLN 0.24
- MACD
- AMRN 0.01
- MOLN 0.04
- Stochastic Oscillator
- AMRN 96.99
- MOLN 49.91
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.